Skip to main content

Table 2 Clinical characteristics of patients at baseline and after 24 and 48 weeks of adalimumab treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

Variable Week 0 Week 24 P Week 48 P
DAS 28 5.4 ± 1.3 3.6 ± 1.2 <0.01 2.7 ± 0.9 <0.01
Tender joint count 12.4 ± 4.7 5.1 ± 3.5 <0.01 4.9 ± 3.5 <0.01
Swollen joint count 10.4 ± 3.8 3.2 ± 3.4 <0.01 3.12 ± 3.4 <0.01
ESR (mm/h) 35 ± 17 26 ± 16 <0.01 24 ± 15 <0.01
CRP (mg/dl) 42 ± 22.7 21 ± 15.2 <0.01 15 ± 14.8 <0.01
Anti-CCP (AU)a 116.9 ± 43.6 100.5 ± 46.5 <0.01 78.5 ± 43.9 <0.01
RF (IU) 121.7 ± 120.6 81 ± 90 <0.01 70.2 ± 82.7 <0.01
  1. aOnly anti-CCP positive patients at baseline (46 of 57) were included in the evaluation. Results are mean values ± SD. AU, arbitrary units; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS 28 = Disease Activity Score; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.